Galderma Group AG
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 114
- Registration Number
- NCT01789775
- Locations
- 🇸🇪
Galderma Investigational Site, Eskilstuna, Sweden
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 18
- Registration Number
- NCT01766440
- Locations
- 🇺🇸
Menter Dermatology Research Institute, Dallas, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Rady Children's Hospital - Pediatric and Adolescent Dermatology, San Diego, California, United States
Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 75
- Registration Number
- NCT01753830
Treatment of Pectus Excavatum Deformity Using Macrolane Filler
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 23
- Registration Number
- NCT01750112
- Locations
- 🇸🇪
Per Heden, Stockholm, Sweden
🇫🇷Raphael Sinna, Amiens, France
Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 40
- Registration Number
- NCT01745250
- Locations
- 🇩🇪
Medical Skin center, Dusseldorf, Germany
A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
- Conditions
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 38
- Registration Number
- NCT01688531
- Locations
- 🇫🇷
Galderma Investigational site, Nantes, France
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 70
- Registration Number
- NCT01659853
- Locations
- 🇺🇸
DermResearch, Inc, Austin, Texas, United States
🇺🇸The Education & Research Foundation, Inc., Lynchburg, Virginia, United States
🇺🇸Hudson Dermatology, Evansville, Indiana, United States
Dose Range Study of CD5789 in Acne Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 304
- Registration Number
- NCT01616654
- Locations
- 🇺🇸
Hamzavi Dermatology, Fort Gratiot, Michigan, United States
🇺🇸Palmetto Clinical Trial Services, LLC, Greenville, South Carolina, United States
🇺🇸Somerset Skin Centre, Troy, Michigan, United States
An Extension of CTN 31GB0607 to Evaluate Long Term Safety of NASHA Treatment in the Breast
- Conditions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 11
- Registration Number
- NCT01609400
Anesthetic Effect Duration Assessment
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 30
- Registration Number
- NCT01545765
- Locations
- 🇺🇸
Galderma Investigational center, Rochelle Park, New Jersey, United States